Ping Li

发表

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment

B. Shao, Huiping Li, Ling Zhu, 2022, Frontiers in Bioengineering and Biotechnology.

Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer

Zhongtao Zhang, Wei Xu, Yaqian Xu, 2022, Frontiers in Oncology.

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

B. Graves, A. Chicas, K. Wood, 2023, Targeted Oncology.

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With dMMR Metastatic Colorectal Cancer: A Multicenter Cohort Study

Yunjiu Cheng, Shu-biao Ye, P. Chen, 2021, SSRN Electronic Journal.

IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer

Jianjun Zhou, Yunfei Gao, Xiao Wang, 2021, Frontiers in Oncology.

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

H. Kantarjian, J. Cortes, Sangmin Lee, 2018, Blood.

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

J. Cortes, Sangmin Lee, G. Schiller, 2018 .

Transdermal delivery of brucine-encapsulated liposomes significantly enhances anti-tumor outcomes in treating triple-negative breast cancer

Chengpan Li, Meng-Ran Xu, Yi Hu, 2023, Biomaterials Advances.

Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

M. Sowa, L. Poling, Yanke Liang, 2023, Cancer Research.

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Yun Wei, Yumiao Feng, G. Ding, 2018 .